American International Group Inc. trimmed its holdings in Simulations Plus, Inc. (NASDAQ:SLP) by 3.5% in the 4th quarter, according to its most recent disclosure with the SEC. The firm owned 9,474 shares of the technology company’s stock after selling 347 shares during the period. American International Group Inc.’s holdings in Simulations Plus were worth $681,000 at the end of the most recent quarter.
A number of other large investors have also recently added to or reduced their stakes in the business. US Bancorp DE lifted its stake in Simulations Plus by 41.0% during the fourth quarter. US Bancorp DE now owns 1,317 shares of the technology company’s stock worth $95,000 after purchasing an additional 383 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank lifted its stake in Simulations Plus by 20.4% during the fourth quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 2,356 shares of the technology company’s stock worth $169,000 after purchasing an additional 400 shares in the last quarter. Vantage Consulting Group Inc acquired a new position in Simulations Plus during the fourth quarter worth $53,000. Eqis Capital Management Inc. lifted its stake in Simulations Plus by 24.6% during the fourth quarter. Eqis Capital Management Inc. now owns 3,832 shares of the technology company’s stock worth $276,000 after purchasing an additional 756 shares in the last quarter. Finally, Citigroup Inc. lifted its stake in Simulations Plus by 30.9% during the fourth quarter. Citigroup Inc. now owns 3,463 shares of the technology company’s stock worth $249,000 after purchasing an additional 818 shares in the last quarter. Institutional investors own 60.75% of the company’s stock.
A number of research firms have commented on SLP. Oppenheimer upped their price target on Simulations Plus from $79.00 to $85.00 in a research note on Tuesday, January 12th. TheStreet upgraded Simulations Plus from a “c+” rating to a “b” rating in a research note on Friday, January 8th. Zacks Investment Research upgraded Simulations Plus from a “sell” rating to a “hold” rating in a research note on Wednesday, January 13th. Finally, Craig Hallum cut Simulations Plus from a “buy” rating to a “hold” rating in a research note on Tuesday, January 12th. Two analysts have rated the stock with a hold rating and three have assigned a buy rating to the stock. The stock currently has a consensus rating of “Buy” and an average target price of $81.60.
Simulations Plus stock opened at $63.98 on Thursday. Simulations Plus, Inc. has a 1-year low of $32.18 and a 1-year high of $90.92. The stock has a market cap of $1.28 billion, a PE ratio of 125.45, a P/E/G ratio of 8.45 and a beta of -0.07. The stock’s fifty day moving average is $67.89 and its two-hundred day moving average is $69.71.
Simulations Plus (NASDAQ:SLP) last posted its quarterly earnings results on Sunday, January 10th. The technology company reported $0.12 earnings per share for the quarter, beating the Zacks’ consensus estimate of $0.11 by $0.01. Simulations Plus had a return on equity of 10.65% and a net margin of 22.74%. The company had revenue of $10.70 million for the quarter, compared to analysts’ expectations of $10.56 million. As a group, analysts anticipate that Simulations Plus, Inc. will post 0.57 earnings per share for the current year.
The firm also recently declared a quarterly dividend, which was paid on Monday, February 1st. Shareholders of record on Monday, January 25th were paid a $0.06 dividend. This represents a $0.24 dividend on an annualized basis and a yield of 0.38%. The ex-dividend date was Friday, January 22nd. Simulations Plus’s dividend payout ratio is presently 42.86%.
About Simulations Plus
Simulations Plus, Inc develops drug discovery and development software for mechanistic modeling and simulation, and prediction of properties of molecules utilizing artificial-intelligence- and machine-learning-based technology worldwide. The company offers GastroPlus, which simulates the absorption, pharmacokinetics (PK), pharmacodynamics, and drug-drug interactions of compounds administered to humans and animals; DDDPlus that simulates in vitro laboratory experiments; and MembranePlus, which simulates laboratory experiments.
Further Reading: How does equity income fit into an investing strategy?
Want to see what other hedge funds are holding SLP? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Simulations Plus, Inc. (NASDAQ:SLP).
Receive News & Ratings for Simulations Plus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Simulations Plus and related companies with MarketBeat.com's FREE daily email newsletter.